melanotan-2 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-08 and is reviewed periodically as new material appears.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
== Other developments because of reverse vaccinology and bioinformatics == Reverse vaccinology has caused an increased focus on pathogenic biology. Reverse vaccinology led to the discovery of pili in gram-positive pathogens such as A streptococcus, B streptococcus, and pneumococcus. Previously, all gram-positive bacteria were thought to not have any pili. Reverse vaccinology also led to the discovery of factor G binding protein in meningococcus, which binds to complement factor H in humans. Binding to the complement factor H allows for meningococcus to grow in human blood while blocking alternative pathways. This model does not fit many animal species, which do not have the same complement factor H as humans, indicating differentiation of meningococcus between differing species.
== Approval and use == Tofisopam is not approved for sale in the United States or Canada. However, Vela Pharmaceuticals of New Jersey is developing the D-enantiomer (dextofisopam) as a treatment for irritable bowel syndrome, with moderate efficacy demonstrated in clinical trials so far.
Gene expression is the process by which the information contained within a gene is used to produce a functional gene product, such as a protein or a functional RNA molecule. This process involves multiple steps, including the transcription of the gene's sequence into RNA. For protein-coding genes, this RNA is further translated into a chain of amino acids that folds into a protein, while for non-coding genes, the resulting RNA itself serves a functional role in the cell. Gene expression enables cells to utilize the genetic information in genes to carry out a wide range of biological functions. While expression levels can be regulated in response to cellular needs and environmental changes, some genes are expressed continuously with little variation.
There is evidence supporting the use of minoxidil as a safe and effective treatment for female pattern hair loss, and there is no significant difference in efficiency between 2% and 5% formulations. Finasteride was shown to be no more effective than placebo based on low-quality studies. The effectiveness of laser-based therapies is unclear. Bicalutamide, an antiandrogen, is another option for the treatment of female pattern hair loss.
Sources: en.wikipedia.org
Applied Biosystems is one of various brands under the Life Technologies brand of Thermo Fisher Scientific corporation. The brand is focused on integrated systems for genetic analysis, which include computerized machines and the consumables used within them (such as reagents). In 2008, a merger between Applied Biosystems and Invitrogen was finalized, creating Life Technologies. The latter was acquired by Thermo Fisher Scientific in 2014. Prior to 2008, the Applied Biosystems brand was owned by various entities in a corporate group parented by PerkinElmer. The roots of Applied Biosystems trace back to GeneCo (Genetic Systems Company), a pioneer biotechnology company founded in 1981 in Foster City, California. Through the 1980s and early 1990s, Applied Biosystems, Inc. operated independently and manufactured biochemicals and automated genetic engineering and diagnostic research instruments, including the principal brand of DNA sequencing machine used by the Human Genome Project consortium centers. Applied Biosystems' close ties to the consortium project led to the idea for the founding of Celera Genomics in 1998 as one of several independent competitors to the consortium. In 1993 Applied Biosystems, Inc., was delisted from the NASDAQ when it was acquired by the old company known then as Perkin-Elmer. As the PE Applied Biosystems Division under that parent in 1998, it became consolidated with other acquisitions as the primary PE Biosystems Division.
== External links == PL-6983 for Sexual Dysfunction - Palatin Technologies PL-6983 for Female Sexual Dysfunction - Palatin Technologies Palatin Obtains $21.1M to Advance Programs in Female Sexual Dysfunction and Asthma - Genetic Engineering and Biotechnology News Research Programme: Sexual Dysfunction Therapy (PL-6983) - Palatin Technologies - AdisInsight How Sildenax Works? Composition & Benefits of Sildenax - Nutri Medi How Medicines Work To Improve Potency - Vera Farmacia
isochore A large region of genomic DNA with a relatively homogeneous composition of base pairs, distinguished from other regions by the proportion of pairs that are G-C or A-T. The genomes of most plants and vertebrates are composed of different classes of GC-rich and AT-rich isochores.
Kissinger told Nixon: "While we have a moral case for bombing North Vietnam when it does not accept our terms, it seems to be really stretching the point to bomb North Vietnam when it has accepted our terms and when South Vietnam has not". As expected, Tho refused to consider any of the 69 amendments, and on 13 December 1972, he left Paris for Hanoi after accusing the Americans of negotiating in bad faith. Kissinger, by this stage, was worked up into a state of fury after Tho walked out of the Paris talks and told Nixon: "They're just a bunch of shits. Tawdry, filthy shits. They make the Russians look good, compared to the way the Russians make the Chinese look good when it comes to negotiating in a responsible and decent way". The National Security Advisor now advised Nixon to bomb North Vietnam to make them "talk seriously".
== Taxonomy == The classification of this species has been revised in recent decades. Puffballs, earthballs, earthstars, stinkhorns and several other kinds of fungi were once thought to be related and were known as the gasteromycetes or 'stomach' fungi, because the fertile material develops inside spherical or pear-shaped fruiting bodies; however, this group is now known to be polyphyletic. Today, some authors place the giant puffball and other members of the genus Calvatia in order Agaricales. The giant puffball has also been placed in two other genera, Lycoperdon and Langermannia, in years past. The current view is that the giant puffball belongs in Calvatia.
Sources: en.wikipedia.org
=== Cognition === Despite some studies suggesting that sugar consumption causes hyperactivity, the quality of evidence is low and it is generally accepted within the scientific community that the notion of children's "sugar rush" is a myth. A 2019 meta-analysis found that sugar consumption does not improve mood, but can lower alertness and increase fatigue within an hour of consumption. One review of low-quality studies of children consuming high amounts of energy drinks showed association with higher rates of unhealthy behaviours, including smoking and excessive alcohol use, and with hyperactivity and insomnia, although such effects could not be specifically attributed to sugar over other components of those drinks such as caffeine.
2 November – Andy Street, the Mayor of the West Midlands, has written to the Home Secretary requesting that his office be granted the powers of the area's Police and Crime Commissioner after the next mayoral election because "crime in this region has more than doubled... and I simply cannot allow it to go on any longer". 5 November – The Metropolitan Police ends its relationship with adviser Attiq Malik after video emerged of him chanting a pro-Palestinian slogan during a speech to a group in 2021. Surrey County Council declares an emergency after thousands of properties are left without water following a technical problem at a Thames Water treatment works, which is attributed to Storm Ciarán. 7 November – Anastrozole, a drug used for a number of years to treat breast cancer, is licensed for use in England as a preventative option. West Yorkshire Police launch a murder investigation after a 15-year-old boy dies following a stabbing near a school in Leeds. He is later named as Alfie Lewis, a former student at Horsforth School. 9 November – A 14-year-old boy is remanded in custody charged with the murder of Alfie Lewis. Labour's Caroline Woodley is elected mayor of Hackney in London in a by-election. 10 November – Following trial and conviction at Leicester Crown Court, Katie Tidmarsh is sentenced to life imprisonment with a minimum term of 17 years for the 2012 murder of Ruby Thompson, a one-year-old child she had hoped to adopt.
=== Post-translational modifications === Whilst detailed comparison of the MS data with predictions based on the known protein sequence may be used to define post-translational modifications, targeted approaches to data acquisition may also be used. For instance, specific enrichment of phosphopeptides may assist in identifying phosphorylation sites in a protein. Alternative methods of peptide fragmentation in the mass spectrometer, such as ETD or ECD, may give complementary sequence information.
Electromagnetic alternating fields have been used in medicine since 1764, mainly for heating and increasing blood circulation (diathermy, short-wave therapy) to improve wound and bone healing. The relevant radiation protection is regulated by the Medical Devices Act together with the Medical Devices Operator Ordinance. The Medical Devices Act came into force in Germany on January 14, 1985. It divided the medical devices known at that time into groups according to their degree of risk to the patient. The Medical Devices Ordinance regulated the handling of medical devices until January 1, 2002, when it was replaced by the Medical Devices Act. When ionizing radiation is used in medicine, the benefit must outweigh the potential risk of tissue damage (justifiable indication). For this reason, radiation protection is of great importance. The design should be optimized according to the ALARA (As Low As Reasonably Achievable) principle as soon as an application is described as suitable. Since 1996, the European ALARA Network (EAN), founded by the European Commission, has been working on the further implementation of the ALARA principle in radiation protection.
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.